ClinicalTrials.gg
CompletedNCT00848965Updated Sep 24, 2012Results posted

A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber

A Phase 4 interventional study of Fluticasone propionate and Placebo in Rhinitis, Allergic, Perennial and Allergic Rhinitis, sponsored by GlaxoSmithKline. Completed at 1 site in Austria. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-09-24.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies testing fluticasone in Rhinitis, Allergic, Perennial — 1 open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic, Perennial.

Enrollment
18th of 21
59 · median 288
Started
2007
with 3 others
Phase 4
7 of 21
1 open now
Registered
16th of 21
by date
Lead sponsor
18 of 21
GlaxoSmithKline

Among the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, this one is the 18th largest by enrollment, is one of 4 that started in 2007, is one of 7 in phase 4, and was the 16th registered.

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

Browse Rhinitis, Allergic, Perennial studies →

Open to participants now

1 of the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, or all of them as a file.
02

Study summary

This is a single-centre, randomised, double-blind, four-period, incomplete block, crossover study, with 8 days repeat dosing of intranasal Fluticasone Propionate (25, 50, 100, 200ug) and/or placebo in the Vienna Challenge Chamber in subjects with allergic rhinitis.

03

Conditions studied

  • Rhinitis, Allergic, Perennial
  • Allergic Rhinitis

Keywords

  • fluticasone propionate
  • Vienna Challenge Chamber
  • glucocorticosteroids
  • allergic rhinitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is healthy with the exception of seasonal allergic rhinitis. Healthy as determined by a responsible physician, based on a medical evaluation including history, physical examination, laboratory tests, cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding will not introduce additional risk factors and will not interfere with the study procedures.
  • Males and females who are aged between 18 and 65 years of age.

A female is eligible to enter and participate in the study if she is of:

  1. Non- (i.e., physiologically incapable of becoming pregnant), including any female who is post menopausal. For the purposes of this study, post menopausal is defined as 1 year without menses (FSH/LH will be also tested to confirm menopausal status); or
  2. Child bearing potential, has a negative pregnancy test (urine) at entry, and agrees to one of the following acceptable methods when used consistently and correctly (i.e., in accordance with the approved product label and the instructions of a physician for the duration of the study - screening visit to follow-up contact):

    • Complete abstinence from intercourse from the first visit, throughout the trial and for a minimum of 7 days after the completion of the trial; or
    • Male partner was sterile prior to the female subject's entry into the study, or
    • Implants of levonorgestrel inserted for at least 1 month prior to the study
    • Injectable progestogen administered for at least 1 month prior to the study
    • Oral contraceptive (combined or progestogen only) administered for a least one monthly cycle prior to study medication administration; or
    • The contraceptive transdermal patch, such as norelgestromin / ethinyl estradiol transdermal system (if the subject is less than 89kg); or
    • Double-barrier method - spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a spermicide and female diaphragm .
    • Condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; or
    • An intrauterine device (IUD) or intrauterine system (IUS), inserted by a qualified physician,
    • Subjects who are current non-smokers, who have not used any inhaled tobacco products (snuff is permitted) in the 12 month period preceding the screening visit and who have a pack history of less than 10 pack years.

Pack years = Number of cigarettes per day x Number of years smoked 20

  • They exhibit a moderate response to up to 1500 grass pollen grains/m3 after 2 hours in the Vienna Challenge Chamber, which is defined as a nasal symptom score of at least 6. (Nasal symptom score is the sum of nasal obstruction, rhinorrhoea, nasal itch and sneeze, each of which are scored on a scale from 0 to 3)
  • They have a positive skin prick test (wheal ³ 4mm) for grass pollen at or within the 12 months preceding the screening visit.
  • They have a positive RAST (Radioallergosorbent Test) (³ class 2) for grass pollen at or within the 12 months preceding the screening visit.
  • They have a TNSS score (Total Nasal Symptom Score)of less than 3 and a score of no more than 1 for any single symptom of the TNSS prior to the screening allergen challenge.
  • There are no conditions or factors that would make the subject unlikely to be able to stay in the trial
  • Able to provide written .
  • The subject is able to understand and comply with the protocol requirements, instructions and protocol-stated restrictions.
  • Demonstrated ability to use the intranasal device in a satisfactory and repeatable manner.

Exclusion criteria

Exclusion Criteria:

  • As a result of medical interview, physical examination or screening investigations, the principle investigator or delegate physician deems the subject unsuitable for the study. Subjects must not have a systolic blood pressure above 150 mmHg or a diastolic pressure above 90 mmHg unless the Investigator confirms that it is satisfactory for their age.
  • The subject has been treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness.
  • Pregnant or nursing females.
  • Women of who are unwilling or unable to use an appropriate method of as outlined (Inclusion Criteria 2)
  • On examination the subject is found to have any structural nasal abnormalities or nasal polyposis, a history of frequent nosebleeds, recent nasal surgery or recent (within 2 weeks) or ongoing upper respiratory tract infection which in the Responsible Physician's opinion renders the subject unsuitable for participation in the study.
  • Any respiratory disease other than mild stable asthma that is controlled with occasional use of as-needed short-acting beta-agonists and associated with normal lung function.
  • The subject is likely to be unable to abstain from salbutamol use for 8 hours before a challenge.
  • The subject has a screening value >450msec (based on single or average QTc value of triplicate ECGs obtained over a brief recording period), PQ interval outside the range 120 to 200msec or an that is not suitable for QT measurements (e.g. poorly defined termination of the T-wave). In addition subjects will be excluded if they have a history of atrial or ventricular arrhythmia.
  • The subject has a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
  • The subject has taken prescription or non-prescription drugs, within 7 days prior to the first dose of study medication, unless in the opinion of the Investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety.
  • History of alcohol/drug abuse or dependence within 12 months of the study. Abuse of alcohol defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). 1 unit is equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass (125ml) of wine).
  • The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • The subject has donated a unit of blood (450 mL) within the previous 16 weeks or intends to donate within 16 weeks after completing the study.
  • A positive pre-study surface antigen or positive antibody result within 3 months of screening.
  • The subject has tested positive for antibodies (if tested according to site Standard Operating Procedures).
  • The subject has a positive pre-study urine drug/ urine alcohol screen. A minimum list of drugs that will be screened for include Amphetamines, Barbiturates, Cocaine, Opiates, Cannabinoids (THC) and Benzodiazepines.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Fluticasone propionate 25ug

    Drug: Fluticasone propionate

  • Experimental
    Fluticason propionate 50ug

    Drug: Fluticasone propionate

  • Experimental
    Fluticasone propionate 100ug

    Drug: Fluticasone propionate

  • Experimental
    Flutciasone propionate 200ug

    Drug: Fluticasone propionate

Interventions

06

What researchers measure

Primary outcomes

  1. Weighted Mean Total Nasal Symptom Score (TNSS) at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge [PSC]) in the Vienna Challenge Chamber (VCC)

    The TNSS (score of 0-12), defined as the sum of the symptom scores for nasal obstruction, rhinorrhea, nasal itch, and sneeze (each scored on 0-3 scale \[0=none, 1=mild, 2=moderate, 3=severe\]) was measured at pre-challenge, and then every 15 minutes from 0.25 to 4 hours PSC. In the VCC, aerosolized allergen is administered in a sealed chamber to evaluate the efficacy of antihistamines/other treatments. Weighted mean TNSS was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.

    Time frame: Day 8 of each study period (Periods 1-4); up to Day 158

Secondary outcomes

  1. Weighted Mean Nasal Airflow at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)

    Allergic rhinitis decreases the passage of air through the nose (nasal airflow) by increasing the nasal airway resistance. Rhinomanometry is used as an objective measurement of airway resistance. Nasal airflow was measured using active anterior rhinomanometry at pre-challenge, and then every 30 minutes from 0.5 to 4 hours post start of VCC. Weighted mean nasal airflow was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.

    Time frame: Day 8 of each study period (Periods 1-4); up to Day 158

  2. Weighted Mean Nasal Secretion at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)

    Nasal secretion was measured by weighing tissues used by participants. Wet tissue weight assessments were made pre-challenge, and then every 30 minutes from 0.5 to 4 hours post start of challenge chamber throughout the study. Weighted mean nasal secretion was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.

    Time frame: Day 8 of each study period (Periods 1-4); up to Day 158

  3. Weighted Mean Eye Symptom Score at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)

    The eye symptom score (total score of 0 \[none\] to 9 \[severe\]) was calculated as the sum of the symptom scores for watery eyes, itchy eyes, and red eyes, each of which was scored on a categorical scale from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), and was measured at pre-challenge, and then every 15 minutes from 0.25 to 4 hours post-start of challenge chamber. Weighted mean eye symptom score was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.

    Time frame: Day 8 of each study period (Periods 1-4); up to Day 158

  4. Weighted Mean Global Symptom Score (GSS) at 5 Hours Post-dose (1-4 Hours Post-start of Challenge)

    GSS (total score=0-30) is calculated as the sum of sneeze, nasal itch, rhinorrhea, nasal obstruction, cough, itchy throat, itchy ears, watery eyes, itchy eyes, and red eyes SSs, each of which was scored on a categorical scale from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), as was measured at pre-challenge, and then every 15 mins from 0.25 to 4 hours post-start of challenge chamber. Weighted mean global symptom score was evaluated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.

    Time frame: Day 8 of each study period (Periods 1-4); up to Day 158

  5. Glucocorticoid (GC) Receptor Biomarker Levels in Nasal Epithelial Scraping Samples: CCL2

    AROS Applied Biotechnology (AB) analyzed the nasal epithelial scrapings of participants and generated TaqMan (type of chemistry developed by AB to detect polymerase chain reaction \[PCR\] products) messenger ribonucleic acid (mRNA) biomarker expression data for CCL2, a steroid-responsive gene. Preliminary analysis of the mRNA abundance data was performed by Discovery Statistics. mRNA abundance data were normalized to the scores of GAPDH and 18S housekeeping genes. B-actin was not used. CCL2 data are presented by period to show the treatment-by-period interaction. ng, nanograms.

    Time frame: Day 1 (pre-dose) and Day 8 of each study period (Periods 1-4); up to Day 158

  6. Glucocorticoid (GC) Receptor Biomarker Levels in Nasal Epithelial Scraping Samples: 18S, B-actin, DUSP_1_T1, FKBP5, GAPDH, GILZ, PLAU, PTGS2, and RGS2

    AROS Applied Biotechnology (AB) analyzed the nasal epithelial scrapings of participants and generated TaqMan (type of chemistry developed by AB to detect polymerase chain reaction \[PCR\] products) messenger ribonucleic acid (mRNA) biomarker expression data for 7 steroid-responsive genes (DUSP_1_TI, FKBP5, GILZ, PLAU, CCL2, PTGS2, and RGS2) and 3 housekeeping reference genes (GAPDH, 18S, and b-actin). Preliminary analysis of the mRNA abundance data was performed by Discovery Statistics. mRNA abundance data were normalized to the scores of GAPDH and 18S housekeeping genes. B-actin was not used.

    Time frame: Day 1 (pre-dose) and Day 8 of each study period (Periods 1-4); up to Day 158

07

Results

Posted Sep 24, 2012

Participant flow

Participant flow — Overall Study
MilestonePlacebo/FP 25, 50, 100, 200 µg
Started59
Completed57
Not completed2
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryWeighted Mean Total Nasal Symptom Score (TNSS) at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge [PSC]) in the Vienna Challenge Chamber (VCC)

The TNSS (score of 0-12), defined as the sum of the symptom scores for nasal obstruction, rhinorrhea, nasal itch, and sneeze (each scored on 0-3 scale \[0=none, 1=mild, 2=moderate, 3=severe\]) was measured at pre-challenge, and then every 15 minutes from 0.25 to 4 hours PSC. In the VCC, aerosolized allergen is administered in a sealed chamber to evaluate the efficacy of antihistamines/other treatments. Weighted mean TNSS was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.

Time frame:
Day 8 of each study period (Periods 1-4); up to Day 158
Reported as:
Mean · scores on a scale
Weighted Mean Total Nasal Symptom Score (TNSS) at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge [PSC]) in the Vienna Challenge Chamber (VCC)
scores on a scalePlacebo25 µg FP50 µg FP100 µg FP200 µg FP
Weighted Mean Total Nasal Symptom Score (TNSS) at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge [PSC]) in the Vienna Challenge Chamber (VCC)7.17 ± 2.9125.54 ± 2.4375.66 ± 2.2805.29 ± 2.2184.77 ± 2.433
Statistical analysis
  • Placebo vs 25 µg FP · Mean difference (final values): -1.38 · 95% CI -2.08 to -0.68Treatment difference (FP minus placebo) is presented as the difference in the adjusted means for treatment versus placebo.
  • Placebo vs 50 µg FP · Mean difference (final values): -1.55 · 95% CI -2.16 to -0.93Treatment difference (FP minus placebo) is presented as the difference in the adjusted means for treatment versus placebo.
  • Placebo vs 100 µg FP · Mean difference (final values): -1.72 · 95% CI -2.33 to -1.11Treatment difference (FP minus placebo) is presented as the difference in the adjusted means for treatment versus placebo.
  • Placebo vs 200 µg FP · Mean difference (final values): -1.90 · 95% CI -2.60 to -1.19Treatment difference is presented as the difference in the adjusted means for treatment versus placebo.
SecondaryWeighted Mean Nasal Airflow at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)

Allergic rhinitis decreases the passage of air through the nose (nasal airflow) by increasing the nasal airway resistance. Rhinomanometry is used as an objective measurement of airway resistance. Nasal airflow was measured using active anterior rhinomanometry at pre-challenge, and then every 30 minutes from 0.5 to 4 hours post start of VCC. Weighted mean nasal airflow was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.

Time frame:
Day 8 of each study period (Periods 1-4); up to Day 158
Reported as:
Mean · Milliliters per second (mL/s)
Weighted Mean Nasal Airflow at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)
Milliliters per second (mL/s)Placebo25 µg FP50 µg FP100 µg FP200 µg FP
Weighted Mean Nasal Airflow at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)335.20 ± 145.373368.66 ± 144.230375.94 ± 142.105362.59 ± 142.216411.65 ± 160.148
SecondaryWeighted Mean Nasal Secretion at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)

Nasal secretion was measured by weighing tissues used by participants. Wet tissue weight assessments were made pre-challenge, and then every 30 minutes from 0.5 to 4 hours post start of challenge chamber throughout the study. Weighted mean nasal secretion was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.

Time frame:
Day 8 of each study period (Periods 1-4); up to Day 158
Reported as:
Mean · grams (g)
Weighted Mean Nasal Secretion at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)
grams (g)Placebo25 µg FP50 µg FP100 µg FP200 µg FP
Weighted Mean Nasal Secretion at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)2.43 ± 2.2031.63 ± 1.8931.43 ± 1.4581.26 ± 1.5501.02 ± 1.271
SecondaryWeighted Mean Eye Symptom Score at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)

The eye symptom score (total score of 0 \[none\] to 9 \[severe\]) was calculated as the sum of the symptom scores for watery eyes, itchy eyes, and red eyes, each of which was scored on a categorical scale from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), and was measured at pre-challenge, and then every 15 minutes from 0.25 to 4 hours post-start of challenge chamber. Weighted mean eye symptom score was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.

Time frame:
Day 8 of each study period (Periods 1-4); up to Day 158
Reported as:
Mean · scores on a scale
Weighted Mean Eye Symptom Score at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)
scores on a scalePlacebo25 µg FP50 µg FP100 µg FP200 µg FP
Weighted Mean Eye Symptom Score at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)2.35 ± 2.2401.52 ± 1.6781.44 ± 1.7111.93 ± 1.7261.41 ± 1.491
SecondaryWeighted Mean Global Symptom Score (GSS) at 5 Hours Post-dose (1-4 Hours Post-start of Challenge)

GSS (total score=0-30) is calculated as the sum of sneeze, nasal itch, rhinorrhea, nasal obstruction, cough, itchy throat, itchy ears, watery eyes, itchy eyes, and red eyes SSs, each of which was scored on a categorical scale from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), as was measured at pre-challenge, and then every 15 mins from 0.25 to 4 hours post-start of challenge chamber. Weighted mean global symptom score was evaluated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.

Time frame:
Day 8 of each study period (Periods 1-4); up to Day 158
Reported as:
Mean · scores on a scale
Weighted Mean Global Symptom Score (GSS) at 5 Hours Post-dose (1-4 Hours Post-start of Challenge)
scores on a scalePlacebo25 µg FP50 µg FP100 µg FP200 µg FP
Weighted Mean Global Symptom Score (GSS) at 5 Hours Post-dose (1-4 Hours Post-start of Challenge)11.14 ± 5.4078.17 ± 4.3028.24 ± 4.2318.69 ± 4.3467.13 ± 3.487
SecondaryGlucocorticoid (GC) Receptor Biomarker Levels in Nasal Epithelial Scraping Samples: CCL2

AROS Applied Biotechnology (AB) analyzed the nasal epithelial scrapings of participants and generated TaqMan (type of chemistry developed by AB to detect polymerase chain reaction \[PCR\] products) messenger ribonucleic acid (mRNA) biomarker expression data for CCL2, a steroid-responsive gene. Preliminary analysis of the mRNA abundance data was performed by Discovery Statistics. mRNA abundance data were normalized to the scores of GAPDH and 18S housekeeping genes. B-actin was not used. CCL2 data are presented by period to show the treatment-by-period interaction. ng, nanograms.

Time frame:
Day 1 (pre-dose) and Day 8 of each study period (Periods 1-4); up to Day 158
Reported as:
Geometric mean · Copies of RNA detected per 50ng of total
Glucocorticoid (GC) Receptor Biomarker Levels in Nasal Epithelial Scraping Samples: CCL2
Copies of RNA detected per 50ng of totalPlacebo25 µg FP50 µg FP100 µg FP200 µg FP
Period 1, n=12, 12, 12, 11, 1112396.08096 (5928.406 to 25919.75529)1377.248941 (678.7116 to 2794.728503)1231.251053 (605.7205 to 2502.769902)3340.460181 (1599.611 to 6975.866146)3377.403394 (1625.327 to 7018.188693)
Period 2, n=11, 11, 11, 12, 114206.320679 (1991.881 to 8882.624596)2192.232108 (1015.906 to 4730.634081)1765.627412 (849.2589 to 3670.781431)2342.488506 (1127.738 to 4865.715164)2821.11204 (1355.137 to 5872.967075)
Period 3, n=11, 11, 11, 12, 124135.167835 (1987.132 to 8605.171059)3612.444351 (1730.839 to 7539.553498)2184.76185 (1051.383 to 4539.910315)1229.316666 (609.3241 to 2480.157112)2505.03196 (1234.885 to 5081.594294)
Period 4, n=12, 11, 11, 11, 1210111.38124 (5019.348 to 20369.18487)3523.276415 (1674.529 to 7413.114228)2615.352938 (1249.52 to 5474.157686)1917.918706 (889.5355 to 4135.205377)1071.598621 (515.8547 to 2226.060108)
SecondaryGlucocorticoid (GC) Receptor Biomarker Levels in Nasal Epithelial Scraping Samples: 18S, B-actin, DUSP_1_T1, FKBP5, GAPDH, GILZ, PLAU, PTGS2, and RGS2

AROS Applied Biotechnology (AB) analyzed the nasal epithelial scrapings of participants and generated TaqMan (type of chemistry developed by AB to detect polymerase chain reaction \[PCR\] products) messenger ribonucleic acid (mRNA) biomarker expression data for 7 steroid-responsive genes (DUSP_1_TI, FKBP5, GILZ, PLAU, CCL2, PTGS2, and RGS2) and 3 housekeeping reference genes (GAPDH, 18S, and b-actin). Preliminary analysis of the mRNA abundance data was performed by Discovery Statistics. mRNA abundance data were normalized to the scores of GAPDH and 18S housekeeping genes. B-actin was not used.

Time frame:
Day 1 (pre-dose) and Day 8 of each study period (Periods 1-4); up to Day 158
Reported as:
Geometric mean · RNA copies detected per 50 ng total RNA
Glucocorticoid (GC) Receptor Biomarker Levels in Nasal Epithelial Scraping Samples: 18S, B-actin, DUSP_1_T1, FKBP5, GAPDH, GILZ, PLAU, PTGS2, and RGS2
RNA copies detected per 50 ng total RNAPlacebo25 µg FP50 µg FP100 µg FP200 µg FP
18S6439292568 (5953473924 to 6964755253)6109603485 (5653823536 to 6602125890)5822423622 (5388052053 to 6291813164)6218835383 (5759650434 to 6714628599)6222906532 (5758553637 to 6724703483)
B-actin1978137.142 (1761487.822 to 2221432.646)1481307.983 (1316851.063 to 1666303.352)1629006.342 (1448708.283 to 1831743.28)1630387.679 (1451329.134 to 1831537.671)1543748.32 (1374839.809 to 1733408.402)
DUSP_1_T1107004.8077 (87973.18828 to 130153.6195)104633.517 (85852.10596 to 127523.6379)107031.4158 (88881.02888 to 128888.2916)118158.2593 (97226.90284 to 143595.7933)113323.9632 (91653.05005 to 140118.8573)
FKBP528739.3975 (24256.97193 to 34050.12675)155791.0745 (131185.2632 to 185012.0837)174963.5715 (147311.3952 to 207806.4043)177935.1307 (150181.7514 to 210817.2961)151362.3934 (127521.6515 to 179660.2684)
GAPDH5776051.293 (5326118.123 to 6263993.356)6143058.472 (5659602.91 to 6667811.859)6451580.253 (5943884.286 to 7002640.993)6008446.351 (5540570.46 to 6515832.227)5972472.493 (5507396.953 to 6476821.624)
GILZ13601.9459 (11833.92763 to 15634.1105)26629.75763 (23090.34785 to 30711.70672)29304.22353 (25490.27435 to 33688.8299)28832.53255 (25122.37093 to 33090.62412)27304.24721 (23763.4653 to 31372.60943)
PLAU26364.53138 (22020.16973 to 31565.99261)18550.2079 (15417.62826 to 22319.27033)18810.56868 (15681.73421 to 22563.67116)20918.214 (17454.94721 to 25068.63365)21692.66346 (18117.03777 to 25973.98394)
PTGS242479.35246 (34135.93482 to 52862.04685)31120.01509 (24904.20116 to 38887.22762)35049.7556 (28101.49486 to 43716.01489)38443.85612 (30827.02769 to 47942.67187)33657.71928 (27031.4341 to 41908.32284)
RGS255084.11432 (45323.01163 to 66947.44108)45255.7763 (37098.26279 to 55207.04028)54186.44212 (44490.27052 to 65995.78907)50507.30739 (41546.43595 to 61400.88895)50373.91657 (41440.13318 to 61233.67074)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/46 (0%)4/46 (8.7%)
25 µg FP—0/46 (0%)6/46 (13%)
50 µg FP—0/46 (0%)3/46 (6.5%)
100 µg FP—0/46 (0%)2/46 (4.3%)
200 µg FP—0/47 (0%)1/47 (2.1%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlacebo25 µg FP50 µg FP100 µg FP200 µg FP
HeadacheNervous system disorders3/463/461/460/460/47
NasopharygitisInfections and infestations1/462/460/460/461/47
Bronchitis bacterialInfections and infestations0/461/460/460/460/47
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders0/460/461/461/460/47
CoughRespiratory, thoracic and mediastinal disorders0/460/460/461/460/47
RhinorrheaRespiratory, thoracic and mediastinal disorders0/460/461/460/460/47
Abdominal pain upperGastrointestinal disorders0/461/460/460/460/47
NauseaGastrointestinal disorders0/460/461/460/460/47
VomitingGastrointestinal disorders0/460/461/460/460/47
Ear painEar and labyrinth disorders0/460/461/460/460/47

Baseline characteristics

Age Continuous
Age Continuous(Years)Placebo/FP 25, 50, 100, 200 µg
Mean27.2 ± 5.30
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/FP 25, 50, 100, 200 µg
Female30
Male29
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo/FP 25, 50, 100, 200 µg
Japanese/East Asian Heritage (EAH)/South EAH1
White58
08

Study locations

1 site
  • GSK Investigational Site
    Vienna, A-1150, Austria
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2009
First posted
Feb 23, 2009
Start
Oct 2007
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Sep 24, 2012
Last update
Sep 24, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00848965
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 23, 2009
Start date
Oct 2007
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Sep 24, 2012
Last update
Sep 24, 2012

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion